Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.

Qu, Wenchun

Wang, Zhen

Hare, Joshua M

Bu, Guojun

Mallea, Jorge M

Pascual, Jorge M

Caplan, Arnold I

Kurtzberg, Joanne

Zubair, Abba C

Kubrova, Eva

Engelberg-Cook, Erica

Nayfeh, Tarek

Shah, Vishal P

Hill, James C

Wolf, Michael E

Prokop, Larry J

Murad, M Hassan

Sanfilippo, Fred P

2022-03-23T15:11:34Z

2022-03-23T15:11:34Z

2020-09

2022-03-23T15:11:33Z

Severe cases of COVID-19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID-19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo-capillary barriers. The authors performed a systematic literature review and random-effects meta-analysis to determine the potential value of MSC therapy for treating COVID-19-infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 117 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO₂ /FiO₂ ratio, alveolo-capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources.

2157-6564

2157-6580

https://hdl.handle.net/10161/24576

eng

Oxford University Press (OUP)

Stem cells translational medicine

10.1002/sctm.20-0146

Lung

Mesenchymal Stem Cells

Humans

Pneumonia, Viral

Coronavirus Infections

Cytokines

Mesenchymal Stem Cell Transplantation

Pandemics

Cell- and Tissue-Based Therapy

Betacoronavirus

Respiratory Distress Syndrome

COVID-19

SARS-CoV-2

Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.

Journal article

Kurtzberg, Joanne|0000-0002-3370-0703

1007

1022

9

Duke

School of Medicine

Clinical Science Departments

Institutes and Centers

Pathology

Pediatrics

Duke Cancer Institute

Institutes and Provost's Academic Units

Initiatives

Duke Innovation & Entrepreneurship

Pediatrics, Transplant and Cellular Therapy

Published

9